Low-molecular-weight polysaccharides from Agaricus blazei Murrill modulate the Th1 response in cancer immunity
| العنوان: | Low-molecular-weight polysaccharides from Agaricus blazei Murrill modulate the Th1 response in cancer immunity |
|---|---|
| المؤلفون: | Liyan Jiang, Shujuan Yao, Yu Lin, Zhipu Yu, Liyan Lv, Jicheng Liu, Liran Cui |
| المصدر: | Oncology Letters |
| بيانات النشر: | D.A. Spandidos, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, T cell, Pharmacology, Immunoadjuvant, Th1, 03 medical and health sciences, Interferon, cancer immunity, medicine, Splenocyte, biology, Chemistry, Interleukin, ovalbumin, Articles, Ovalbumin, 030104 developmental biology, medicine.anatomical_structure, Oncology, biology.protein, immunoadjuvant, Antibody, Agaricus blazei Murrill polysaccharide, CD8, medicine.drug |
| الوصف: | To assess the effect of low-molecular-weight polysaccharides from Agaricus blazei Murrill (ABP-AW1) as an immunoadjuvant therapy for type 1 T-helper (Th1) responses in tumorigenesis, C57BL/6 mice were inoculated subcutaneously with ovalbumin (E.G7-OVA). After 3, 10 and 17 days, the mice were immunized with PBS, OVA alone, or OVA and ABP-AW1, at low (50 µg), intermediate (100 µg) or high (200 µg) doses. Tumor growth was examined and compared among the groups, as were the following parameters: Splenocyte viability/proliferation, peripheral blood CD4+/CD8+ T cell ratio, serum OVA-specific IgG1 and IgG2b, secretion of interleukin (IL)-2 and interferon (IFN)-γ, and IFN-γ production on a single cell level from cultured splenocytes. Tumor growth in mice treated with OVA and ABP-AW1 (100 or 200 µg) was significantly slower, compared with in the other groups at the same time-points. OVA with 100 or 200 µg ABP-AW1 was associated with a higher number of total splenocytes, a higher ratio of peripheral blood CD4+/CD8+ T-lymphocytes, higher serum levels of OVA-specific Th1-type antibody IgG2b and greater secretion of the Th1 cytokines IL-1 and IFN-γ from splenocytes. ABP-AW1 is a promising immunoadjuvant therapy candidate, due to its ability to boost the Th1 immune response when co-administered with a cancer vaccine intended to inhibit cancer progression. |
| اللغة: | English |
| تدمد: | 1792-1082 1792-1074 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f3b2a356fa229878efaded74c9213fTest http://europepmc.org/articles/PMC5796377Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....65f3b2a356fa229878efaded74c9213f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17921082 17921074 |
|---|